Sign In

Marc Stapley

Chief Executive Officer at Veracyte, Inc.

Marc Stapley is the Chief Executive Officer of Veracyte, Inc., a position he has held since June 1, 2021.12 He also serves on the company's board of directors.

Career Background

Stapley has extensive experience in the genomic diagnostics industry:

  • Prior to joining Veracyte, he was Chairman and CEO of Helix, a leading population genomics company, from April 2019 to May 2021.1
  • Before Helix, Stapley held key executive leadership positions at Illumina, the global leader in DNA sequencing technologies, for seven years. His roles included Chief Financial Officer, Chief Administrative Officer, and Executive Vice President.12
  • Earlier in his career, he served as Senior Vice President of Finance at Pfizer Inc.1
  • He has also held senior finance roles at companies like Alcatel-Lucent, Cadence Design Systems, Inc., and Coopers & Lybrand (now PwC).1

Education and Qualifications

  • Stapley holds a B.Sc. (Honors) in Mathematics from The University of Reading in England.12
  • He is a member of the Institute of Chartered Accountants in England and Wales.1

Current Roles and Responsibilities

As CEO of Veracyte, Stapley leads the company's strategic focus on providing molecular diagnostics technology throughout the cancer care cycle.3 Under his leadership, Veracyte has:

  • Expanded its portfolio through acquisitions, such as C2i Genomics, to cover more aspects of cancer diagnosis and treatment monitoring.3
  • Continued to invest in AI and machine learning technologies to enhance their diagnostic capabilities.3

Board Memberships

In addition to his role at Veracyte, Stapley serves on the board of directors for:

  • Helix
  • Glaukos Corporation (GKOS)14

Marc Stapley's leadership and extensive experience in the genomics and diagnostics fields position him well to guide Veracyte's growth and innovation in molecular diagnostics and precision medicine.

Highlights

May 3 · linkedin

I am thrilled to share that today Veracyte published our inaugural Environmental, Social and Governance (#ESG) report. As our company has grown, we have embraced our responsibility to our shareholders, employees, business partners, and the broader community in which we operate.     I'm grateful to the entire Veracyte Team for their collective efforts in driving and reporting on these results, and am excited to get to work on building upon this foundation to advance Veracyte's ESG impact in the future.   To learn more about what Veracyte is doing to advance patient access to cancer care, better understand and reduce our environmental footprint, conduct our business with the highest level of adherence to ethical standards, embrace diversity among our employees, and more, I invite you to read the report here: https://lnkd.in/gy-6uSGH

May 6 · linkedin

I’m excited to share that James Lu, M.D. Ph.D will be taking over as the CEO of Helix and that I will continue to support this amazing company as the Executive Chairman of the Board. With James’ clear vision and proven success, first with the scientific organization, and more recently with his expanded role as President, including his leadership of our commercial organization, I can think of no better leader for Helix as we begin our next chapter of scaling our population genomics platform. Given our accomplishments over the last two years Helix is in the best position it’s ever been to allow every person to benefit from the power of their genome.

Related Questions

What are Marc Stapley's key achievements at Veracyte?
How did Marc Stapley's leadership at Helix impact the company's growth?
What strategies has Marc Stapley implemented at Veracyte?
How does Marc Stapley's background in finance influence his approach to genomic diagnostics?
What is the significance of Veracyte's acquisition of C2i under Marc Stapley's leadership?
M
Add to my network

Location

San Diego, California, United States